title: The long-term effect of tetrabenazine in the management of Huntington disease.
abstract: OBJECTIVE
  To enhance the knowledge on the long-term efficacy and safety of tetrabenazine (TBZ) in managing chorea.
  
  
  METHODS
  We analyzed 68 Huntington disease patients (mean disease duration, 55.8 +/- 34.7 months) who had been treated with TBZ for a mean period of 34.4 +/- 25.2 months (median, 34 months; mode, 48 months; range, 3-104 months). We measured the variation from pretreatment of the motor score of Unified Huntington's Disease Rating Scale at the first follow-up visit and at the latest.
  
  
  RESULTS
  Mean Unified Huntington's Disease Rating Scale-chorea underscore at the time of the pretreatment visit was 10.4 +/- 4.1 (range, 0-28). At the first follow-up, 9.7 +/- 7.8 months after the prescription of TBZ (mean dose, 35.3 +/- 14.7 mg), mean score of chorea was 8.2 +/- 4.1 (-21% compared with baseline), whereas at the latest follow-up visit (mean dose, 57.5 +/- 14.7 mg), it was 9.5 +/- 5.0 (9%). During the follow-up, the clinical benefit persisted, but the magnitude was reduced despite a progressive increase of the doses (up to 60%). Motor improvement was not influenced by sex, or doses or duration of therapy; age at onset was the only predictor of a good outcome. Five patients (7%) did not gain any improvement, and TBZ was discontinued. There were 2 withdrawals because of side effects; 34 patients reported at least 1 side effect.
  
  
  CONCLUSIONS
  Tetrabenazine was well tolerated and produced long-term improvement of motor symptoms in Huntington disease patients, although a slight reduction of benefit occurred during the course of treatment.
authors.affiliation: Istituto di Neurologia, Università Cattolica del Sacro Cuore, Roma, Italy. alfonso.fasano@rm.unicatt.it
authors.forename: Alfonso
authors.initials: A
authors.lastname: Fasano
authors.forename: Federica
authors.initials: F
authors.lastname: Cadeddu
authors.forename: Arianna
authors.initials: A
authors.lastname: Guidubaldi
authors.forename: Carla
authors.initials: C
authors.lastname: Piano
authors.forename: Francesco
authors.initials: F
authors.lastname: Soleti
authors.forename: Paola
authors.initials: P
authors.lastname: Zinzi
authors.forename: Anna Rita
authors.initials: AR
authors.lastname: Bentivoglio
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000328:Adult; D018726:Anti-Dyskinesia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002819:Chorea / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D012189:Retrospective Studies; D013747:Tetrabenazine / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018759:Adrenergic Uptake Inhibitors; D018726:Anti-Dyskinesia Agents; D013747:Tetrabenazine